文献速递物质与行为成瘾

丁丙诺啡治疗阿片类使用障碍者中的加巴喷丁使用

Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

近三分之一接受加巴喷丁者在启动丁丙诺啡后至少发生1次药物相关中毒,但调整分析显示加巴喷丁使用天数与药物相关中毒住院无关(OR 0.98,95%CI 0.85-1.13),风险不随剂量变化。

要点

  • 加巴喷丁在OUD治疗中常用于共病和戒断症状,属超说明书使用。
  • 接受加巴喷丁者药物相关中毒比例更高(31.1% vs 14.5%),但调整后无关联。
  • 加巴喷丁使用天数与药物相关中毒住院的调整OR为0.98(95%CI 0.85-1.13)。

核心结论

  • 调整分析中,加巴喷丁与丁丙诺啡同时使用未增加药物相关中毒风险。
  • 接受加巴喷丁者药物相关中毒住院比例更高,但该关联可能由共病解释。
  • 仍需更多数据评估加巴喷丁在OUD治疗中的安全性。

研究设计与样本

  • 回顾性复发事件病例对照研究,采用交叉设计。
  • 数据来自MarketScan商业和多州医疗补助数据库,2006年1月1日至2016年12月31日。
  • 纳入12至64岁有OUD诊断并开具丁丙诺啡处方者,观察单位为个人日。

主要发现

  • 加巴喷丁更少处方给黑人或西班牙裔患者,更多处方给女性、共病物质使用或心境障碍者、以及神经病理性疼痛等躯体共病者。
  • 调整分析显示加巴喷丁使用天数与药物相关中毒住院无关(OR 0.98,95%CI 0.85-1.13)。
  • 药物相关中毒风险不随加巴喷丁剂量变化。

关键数值与推荐

  • 主要结局为启动丁丙诺啡治疗后90天内接受加巴喷丁和药物相关中毒。
  • 药物相关中毒使用ICD-9和ICD-10编码定义。
  • 加巴喷丁暴露定义为处方覆盖的天数。

临床怎么用

  • 在OUD患者中处方加巴喷丁时,应关注共病情况,但调整分析未显示其增加药物相关中毒风险。
  • 临床决策需结合患者个体共病和潜在风险,不应仅因药物相关中毒史而排除加巴喷丁。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Gabapentin prescriptions have drastically increased in the US due to off-label prescribing in settings such as opioid use disorder (OUD) treatment to manage a range of comorbid conditions and withdrawal symptoms, despite a lack of evidence. OBJECTIVE: To assess the purpose and associated risks of off-label gabapentin use in OUD treatment. DESIGN, SETTING, AND PARTICIPANTS: This retrospective recurrent-event case-control study with a crossover design used administrative claims data from MarketScan Commercial and Multi-State Medicaid databases from January 1, 2006, to December 31, 2016. Individuals aged 12 to 64 years with an OUD diagnosis and filling buprenorphine prescriptions were included in the primary analysis conducted from July 1, 2022, through June 1, 2023. Unit of observation was the person-day. EXPOSURES: Days covered by filled gabapentin prescriptions. MAIN OUTCOMES AND MEASURES: Primary outcomes were receipt of gabapentin in the 90 days after initiation of buprenorphine treatment and drug-related poisoning. Drug-related poisonings were defined using codes from International Classification of Diseases, Ninth Revision, and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. RESULTS: A total of 109 407 patients were included in the analysis (mean [SD] age, 34.0 [11.2] years; 60 112 [54.9%] male). Among the 29 967 patients with Medicaid coverage, 299 (1.0%) were Hispanic, 1330 (4.4%) were non-Hispanic Black, 23 112 (77.1%) were non-Hispanic White, and 3399 (11.3%) were other. Gabapentin was significantly less likely to be prescribed to Black or Hispanic patients, and more likely to be prescribed to female patients, those with co-occurring substance use or mood disorders, and those with comorbid physical conditions such as neuropathic pain. Nearly one-third of persons who received gabapentin (4336 [31.1%]) had at least 1 drug-related poisoning after initiating buprenorphine treatment, compared with 13 856 (14.5%) among persons who did not receive gabapentin. Adjusted analyses showed that days of gabapentin use were not associated with hospitalization for drug-related poisoning (odds ratio, 0.98 [95% CI, 0.85-1.13]). Drug-related poisoning risks did not vary based on dosage. CONCLUSIONS AND RELEVANCE: Gabapentin is prescribed in the context of a myriad of comorbid conditions. Even though persons receiving gabapentin are more likely to have admissions for drug-related poisoning, these data suggest that gabapentin is not associated with an increased risk of drug-related poisoning alongside buprenorphine in adjusted analyses. More data on the safety profile of gabapentin in OUD settings are needed.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ellis MS, Xu KY, Tardelli VS, et al. Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder. JAMA Psychiatry. 2023. PMID: 37672238. doi:10.1001/jamapsychiatry.2023.3145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。